Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,994
  • Shares Outstanding, K 73,732
  • Annual Sales, $ 22,110 K
  • Annual Income, $ -29,310 K
  • 60-Month Beta 2.00
  • Price/Sales 1.73
  • Price/Cash Flow N/A
  • Price/Book 1.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.08
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +56.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4920 +3.62%
on 07/09/20
0.7400 -31.11%
on 06/15/20
-0.1071 (-17.36%)
since 06/10/20
3-Month
0.3163 +61.18%
on 04/21/20
0.7400 -31.11%
on 06/15/20
+0.1598 (+45.66%)
since 04/09/20
52-Week
0.2700 +88.81%
on 03/18/20
1.5400 -66.90%
on 07/15/19
-0.9302 (-64.60%)
since 07/10/19

Most Recent Stories

More News
Adamis Pharmaceuticals Provides Update on SYMJEPI Products

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC ("USWM" or "US WorldMeds") began promoting Adamis' SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine)...

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today the publication of an article entitled "Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl...

ADMP : 0.5177 (-0.44%)
Thinking about buying stock in TOP Ships, Hertz, Biocept, Edesa Biotech, or Adamis Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, HTZ, BIOC, EDSA, and ADMP.

ADMP : 0.5177 (-0.44%)
HTZ : 1.4400 (-0.69%)
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19). The...

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today the publication of an article entitled "An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability...

ADMP : 0.5177 (-0.44%)
Adamis: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Monday reported a loss of $10.3 million in its first quarter.

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business update.

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its ZIMHI (naloxone...

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that it will host an investor conference call on Monday, May 18, 2020 at 2:00 pm Pacific Time to discuss its financial and operating...

ADMP : 0.5177 (-0.44%)
Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI (epinephrine) Injection 0.3mg, SYMJEPI (epinephrine) Injection 0.15mg products...

ADMP : 0.5177 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ADMP with:

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Key Turning Points

2nd Resistance Point 0.5522
1st Resistance Point 0.5337
Last Price 0.5177
1st Support Level 0.4944
2nd Support Level 0.4736

See More

52-Week High 1.5400
Fibonacci 61.8% 1.0549
Fibonacci 50% 0.9050
Fibonacci 38.2% 0.7551
Last Price 0.5177
52-Week Low 0.2700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar